IP Journal of Urology, Nephrology and Hepatology Science

---

Experience of Faropenem for the management of urinary tract infection: Real-world experience from India

Full Text PDF Share on Facebook Share on Twitter

---

Original Article

Author Details : Ashit Shah, Shaleen Sharma*, TK Unnikrishnan

Volume : 3, Issue : 4, Year : 2020

Article Page : 77-81

Suggest article by email

---

Abstract

Background: Urinary tract infections (UTIs) is the infectious diseases affecting both the genders. The prevalence of drug-resistant microbes in patients with UTIs is increasing. Faropenem due to its broad spectrum antimicrobial activity and lower chances of resistance is becoming popular among the Indian urologist however, real-world data is scarce. 
Aim and Objective: To record the real-world responses from the urologist of India on the use of faropenem in the management of UTIs.
Materials and Methods: Responses of Indian urologists were obtained on the usage of faropenem in the management of complicated urinary tract infection (cUTI) after providing a set of eight questions having both multiple-choice responses and open-ended answers. 
Results: Responses of 391 participants were collected. In majority of the urology clinics prevalence of cUTI was 5-10% whereas others found it to be 10-20%. Majority believes that faropenem is an effective pharmacotherapy for the management of UTIs (66.4%) including cUTI as a step-down therapy (66.4%). Faropenem 300 mg provides more compliance. Overall perception on the use of faropenem in their practice was that (out of 391 responses) majority found it to be effective (72.7%) and 4.6% participants have used faropenem as an alternative in cUTI. Majority found it safe (68.5) to be used in cUTI.
Conclusion:  Real world data from the Indian urologist highlight the shifting trend. Faropenem is being referred for the treatment of urinary tract infections due to its effectiveness, ability to cause less resistance and safety profile.

Keywords: Resistance, Urinary tract infection, Extended-spectrum β – lactamase, Penems.

How to cite : Shah A , Sharma S , Unnikrishnan T , Experience of Faropenem for the management of urinary tract infection: Real-world experience from India. J Urol Nephrol Hepatol Sci 2020;3(4):77-81

Copyright © 2020 by author(s) and J Urol Nephrol Hepatol Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)